Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

AstraZeneca Signs Three Biotech Deals

February 5, 2007 | A version of this story appeared in Volume 85, Issue 6

AstraZeneca has entered three deals with biotech companies in a drive to broaden its product pipeline. In one deal, the company will work with U.K.-based Argenta Discovery to identify long-acting muscarinic antagonists and dual-acting muscarinic antagonist-β2 agonist drug candidates for the treatment of chronic obstructive pulmonary disease. Argenta will receive a $21 million up-front fee, research funding, and milestone payments that could bring the deal's total value to $500 million. Separately, AstraZeneca has joined forces with Palatin Technologies to develop small molecules targeting melanocortin receptors for the treatment of obesity. Palatin will receive a $10 million up-front payment and could rake in another $300 million in milestone payments. AstraZeneca also has acquired Arrow Therapeutics for $150 million in a deal expected to close early this year. Arrow specializes in discovery and development of antiviral therapies.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.